Advances in genomics have deepened our understanding of the biology of acute
lymphoblastic leukemia (ALL), defined novel molecular leukemia subtypes, discovered new …

Acute lymphoblastic leukemia (ALL) is a malignant clonal expansion of lymphoid
hematopoietic precursors that exhibit developmental arrest at varying stages of …

Background: Cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) genes are frequently
altered in acute lymphoblastic leukaemia (ALL) patients. The aim of this meta-analysis was …

Objective: Acute lymphoblastic leukemia (ALL) is a frequent malignancy in childhood. The
present study was aimed to investigate the effect of miR-223 in ALL and its underlying …

Although pediatric-like treatment regimen has remarkably improved the survival rates of
adults with acute lymphoblastic leukemia (ALL), the outcome of some adult patients is still …

This study delves into the clinical implications of cyclin-dependent kinase inhibitor 2
(CDKN2) deletion in adult T-lineage acute lymphoblastic leukemia (T-ALL). Among 241 …

Copy number variations (CNVs) are widespread in both pediatric and adult cases of B-cell
acute lymphoblastic leukemia (B-ALL); however, their clinical significance remains unclear …

In addition to somatic mutations, germline genetic predisposition to hematologic
malignancies is currently emerging as an area attracting high research interest. In this study …

Emerging evidence suggested that CDKN2 deletion was a poor prognosis predictor in adult
B-lineage acute lymphoblastic leukemia (B-ALL). Here, we investigated the effect of …

Objective To describe the clinicopathological and genomic features of nine patients with
primary and secondary orbital/ocular manifestations of leukaemia. Methods All orbital/ocular …